Eric M. Dube, chief executive officer of Travere Therapeutics (NASDAQ:TVTX), sold a total of 63,900 shares of the companys common stock on April 15, 2026, generating approximately $2.63 million in proceeds. The transactions, carried out at prices between $41.01 and $42.66 per share, were reported in a Form 4 filing with the Securities and Exchange Commission.
The filing states the sales were executed pursuant to a pre-established 10b5-1 trading plan that Travere adopted on June 16, 2025. A portion of the shares sold was used to satisfy the tax liabilities that arose when performance restricted stock units vested earlier in the month.
On April 13, 2026, Dube received 64,000 shares of Travere common stock at no cost as a result of PSUs that vested upon the companies confirmation of the Food and Drug Administrations approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis, or FSGS. After recording the April transactions, Dube is shown as directly owning 432,886 shares of Travere Therapeutics.
The insider activity came while TVTX shares were trading close to a 52-week high of $43.31, after the stock posted a 181% return over the prior 12 months. InvestingPro analysis, which provides valuation insights across more than 1,400 U.S. equities, indicates that the stock appears undervalued at current levels based on its Fair Value assessment.
Travere has recently cleared a significant regulatory milestone. The companys drug Filspari received full FDA approval for use in reducing proteinuria in both adult and pediatric patients aged 8 years and older who do not have active nephrotic syndrome. The approval identifies Filspari as the first and only FDA-approved therapy for FSGS, creating a new approved treatment option for patients with this rare kidney disease.
Following the FDA decision, several sell-side firms adjusted their outlooks for Travere. Stifel raised its price target to $43 while keeping a Hold rating and noted expectations for a rapid launch. Guggenheim increased its target to $54 and maintained a Buy rating. Cantor Fitzgerald reiterated an Overweight rating, and H.C. Wainwright reiterated a Buy rating with a $47 price target. These analyst updates reflect differing assessments of the companies commercial prospects now that regulatory clearance has been secured.
For investors seeking more detailed coverage of executive transactions and in-depth research on Travere Therapeutics, the companys Pro Research Report is available through InvestingPro.
Key points
- Dube sold 63,900 TVTX shares on April 15, 2026, for about $2.63 million at prices from $41.01 to $42.66.
- He acquired 64,000 shares on April 13, 2026, from vesting PSUs tied to FDA approval of FILSPARI for FSGS, and now directly owns 432,886 shares.
- Analysts updated targets after FDA approval; InvestingPro reports the stock appears undervalued relative to its Fair Value assessment.
Risks and uncertainties
- The stock was trading near its 52-week high after a 181% one-year return, indicating price volatility that could affect investor sentiment in the healthcare and broader equity markets.
- The reported sales were made under a pre-arranged 10b5-1 trading plan, which may influence the timing of transactions and how observers interpret insider activity in the biotech sector.
- Analyst views and price targets vary across firms, reflecting differing expectations about the companies commercial execution and market reception of Filspari in the pharmaceutical and healthcare markets.